Aditxt, Inc., a biotech company, has responded to a comment from the U.S. Securities and Exchange Commission (SEC) regarding its Revised Preliminary Proxy Statement filed on June 18, 2024. The SEC's inquiry pertained to the relationship between the Exchange Agreement and the Merger Agreement that Aditxt entered into in December 2023. Aditxt clarified that the Exchange Agreement, which closed on December 22, 2023, is independent of the Merger Agreement's ongoing and uncertain transactions. The company has already issued Series A-1 Convertible Preferred Stock and fulfilled its obligations under the Exchange Agreement, which are not contingent on the Merger Agreement's completion. Aditxt has amended its Form 8-K to reflect this clarification and acknowledges the need to file a separate proxy statement for stockholder approval if the Merger Agreement proceeds.

Aditxt, Inc., a biotech company, has responded to a comment from the U.S. Securities and Exchange Commission (SEC) regarding its Revised Preliminary Proxy Statement filed on June 18, 2024. The SEC's inquiry pertained to the relationship between the Exchange Agreement and the Merger Agreement that Aditxt entered into in December 2023. Aditxt clarified that the Exchange Agreement, which closed on December 22, 2023, is independent of the Merger Agreement's ongoing and uncertain transactions. The company has already issued Series A-1 Convertible Preferred Stock and fulfilled its obligations under the Exchange Agreement, which are not contingent on the Merger Agreement's completion. Aditxt has amended its Form 8-K to reflect this clarification and acknowledges the need to file a separate proxy statement for stockholder approval if the Merger Agreement proceeds.